Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 4.50p 0.00p 0.00p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

SalvaRx Group plc Issue of US$1 million of Loan Notes by iOx

10/12/2018 7:00am

UK Regulatory (RNS & others)


Salvarx (LSE:SALV)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Salvarx Charts.

TIDMSALV

RNS Number : 8925J

SalvaRx Group plc

10 December 2018

 
 Press Release   10 December 2018 
 

SalvaRx Group plc

("SalvaRx", the "Company" or the "Group")

Further Issue of US$1 million of Convertible Loan Notes by iOx Therapeutics

SalvaRx Group plc (AIM:SALV) is pleased to announce that iOx Therapeutics Limited ("iOx"), its 56.95% subsidiary undertaking, has issued an additional US$1 million of unsecured convertible loan notes ("Notes") under revised terms of the previous Loan Note Instrument constituted by iOx in March 2018.

The funds raised will assist iOx to regain momentum following the delay caused by the previous manufacturing issues announced on 23 July 2018. The existing holders of the loan notes issued in March 2018 have now doubled their original subscriptions such that, US$950,000 of additional Notes have been issued to Portage Biotech Inc. ("Portage") and US$50,000 issued to Oxford Sciences Innovation plc. The aggregate amount of Notes issued by iOx is now US$2 million, of which US$1.9 million is held by Portage.

The terms of the Notes differ from those announced on 8 March 2018 in that there is no automatic conversion of the Notes on the first anniversary following issue, and the discount to the Qualifying Event price increases by 5% for each full year following the first anniversary of the relevant issue.

The Notes now have the following key terms:

1. the Notes entitle the holders thereof to interest of 7% per annum on the principal amount of the Notes. Interest is added to the principal amount of the Notes outstanding to be redeemed or converted, as the case may be;

2. the Notes are convertible into ordinary shares of iOx only on the date on which iOx conducts a sale or listing or it undertakes an eligible third party fundraising of not less than US$2 million (a "Qualifying Event"), or in the event of a default;

   3.    the conversion price of the Notes will be: 

a. If a Qualifying Event occurs within 1 year of the issue of the relevant Notes - the Qualifying Event price with a 25% discount;

b. If a Qualifying Event occurs after 1 year of the issue of the Notes - the Qualifying Event price with a 25% discount plus 5% discount for each additional full year since the first anniversary of the issue of the relevant Notes;

c. If there is an event of default, the higher of (i) the price on the last Qualifying Event and (ii) GBP120 per share (if the Noteholder chooses to convert rather than redeem the Notes for cash).

4. the Notes would only be repayable in cash if there is an event of default and the Noteholder chooses not to convert.

Related Party Transaction

Jim Mellon, Greg Bailey, Ian Walters and Kam Shah are directors of the Company and of Portage, consequently the subscription by Portage for the Notes ("the Transaction") is deemed a related party transaction under the AIM Rules for Companies. Richard Armstrong and Colin Weinberg, being the independent directors for the purposes of the Transaction, consider, having consulted with the Company's Nominated Adviser, that the terms of the Transaction are fair and reasonable insofar as the Company's shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

-Ends-

 
 SalvaRx Group plc 
 Ian Walters (Chief Executive)                  Tel: +1 203-441-5451 
 Northland Capital Partners Limited                  Tel: +44 (0) 20 
  Nominated Adviser and Broker                             3861 6625 
 Matthew Johnson / Edward Hutton (Corporate 
  Finance) 
 Vadim Alexandre (Corporate Broking) 
 Peterhouse Capital Limited                          Tel: +44 (0) 20 
  Joint Broker                                             7469 0932 
  Lucy Williams / Duncan Vasey 
 
 

For more information please visit: www.salvarx.io

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IODEAEANELEPFAF

(END) Dow Jones Newswires

December 10, 2018 02:00 ET (07:00 GMT)

1 Year Salvarx Chart

1 Year Salvarx Chart

1 Month Salvarx Chart

1 Month Salvarx Chart
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191021 15:16:21